$9.89
1.44% yesterday
Nasdaq, Apr 04, 10:00 pm CET
ISIN
US19207A1088
Symbol
COEP
Sector
Industry

Coeptis Therapeutics Stock price

$9.67
-1.33 12.09% 1M
+6.21 179.64% 6M
+4.17 75.82% YTD
+3.08 46.69% 1Y
-191.93 95.20% 3Y
-188.33 95.12% 5Y
-188.33 95.12% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
-0.08 0.82%
ISIN
US19207A1088
Symbol
COEP
Sector
Industry

Key metrics

Market capitalization $32.54m
Enterprise Value $34.09m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.87
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-10.05m
Free Cash Flow (TTM) Free Cash Flow $-6.65m
Cash position $530.00k
EPS (TTM) EPS $-5.65
P/E forward negative
Short interest 0.44%
Show more

Is Coeptis Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Coeptis Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Coeptis Therapeutics:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Coeptis Therapeutics:

Buy
100%

Financial data from Coeptis Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 1.04 1.04
4% 4%
-
-1.04 -1.04
4% 4%
-
- Selling and Administrative Expenses 5.65 5.65
56% 56%
-
- Research and Development Expense 2.33 2.33
65% 65%
-
-9.02 -9.02
56% 56%
-
- Depreciation and Amortization 1.04 1.04
4% 4%
-
EBIT (Operating Income) EBIT -10 -10
53% 53%
-
Net Profit -11 -11
49% 49%
-

In millions USD.

Don't miss a Thing! We will send you all news about Coeptis Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Coeptis Therapeutics Stock News

Neutral
GlobeNewsWire
25 days ago
• COEP forms GEAR Therapeutics, as a majority-owned subsidiary, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for broad range of cancers and other therapeutic modalities.
Neutral
GlobeNewsWire
29 days ago
Leveraging Advanced AI and Robotics to Revolutionize Marketing Strategies in Defense and Security Sectors Leveraging Advanced AI and Robotics to Revolutionize Marketing Strategies in Defense and Security Sectors
Neutral
Business Wire
30 days ago
CENTENNIAL, Colo.--(BUSINESS WIRE)--NUBURU, Inc. (NYSE: BURU), a leading innovator in high-power and high-brightness industrial blue laser technology announced its strategic partnership with COEPTIS' NexGenAI Affiliates Network (NASDAQ: COEP), an innovative provider of artificial intelligence and robotics solutions. This collaboration is a pivotal component of NUBURU's comprehensive Transformat...
More Coeptis Therapeutics News

Company Profile

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company. It develops innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.

Head office United States
CEO David Mehalick
Employees 7
Founded 2017
Website www.coeptistx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today